Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBrodie, Martin
dc.contributor.authorCzapinski, Piotr
dc.contributor.authorPazdera, Ladislav
dc.contributor.authorSander, Josemir
dc.contributor.authorToledo Argany, Manuel
dc.contributor.authorNapoles, Mariana
dc.date.accessioned2022-06-20T08:43:06Z
dc.date.available2022-06-20T08:43:06Z
dc.date.issued2021-12
dc.identifier.citationBrodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021 Dec;6(6):528–536.
dc.identifier.issn2378-8763
dc.identifier.urihttp://hdl.handle.net/11351/7720
dc.descriptionAntiepileptic drug; Cannabinoid; Epilepsy
dc.description.abstractObjective: We assessed the efficacy, safety, and tolerability of cannabidivarin (CBDV) as add-on therapy in adults with inadequately controlled focal seizures. Materials and Methods: One hundred and sixty-two participants (CBDV n=81; placebo n=81) were enrolled. After a 4-week baseline, participants titrated from 400 to 800 mg CBDV twice daily (b.i.d.) (or placebo) over 2 weeks, followed by 6 weeks stable dosing (at 800 mg b.i.d.) and a 12-day taper period. The primary endpoint was the change from baseline in focal seizure frequency during the 8-week treatment period. Secondary endpoints included additional efficacy measures relating to seizures, physician- and participant-reported outcomes, change in the use of rescue medication, cognitive assessments, and safety. Results: Median baseline focal seizure frequencies were 17–18 per 28 days in both groups, and similar reductions in frequency were observed in the CBDV (40.5%) and placebo (37.7%) groups during the treatment period (treatment ratio [% reduction] CBDV/placebo: 0.95 [4.6]; confidence interval: 0.78–1.17 [−16.7 to 21.9]; p=0.648). There were no differences between the CBDV and placebo groups for any seizure subtype. There were no significant treatment differences between CBDV and placebo groups for any of the secondary efficacy outcome measures. Overall, 59 (72.8%) of participants in the CBDV group and 39 (48.1%) in the placebo group had ≥1 treatment-emergent adverse event (AE); the 3 most common were diarrhea, nausea, and somnolence. The incidence of serious AEs was low (3.7% in the CBDV group vs. 1.2% in the placebo group). There was little or no effect of CBDV on vital signs, physical examination, or electrocardiogram findings. Elevations in serum transaminases (alanine aminotransferase or aspartate aminotransferase) to levels >3×upper limit of normal occurred in three participants taking CBDV (two discontinued as a result) and one taking placebo; however, none met the criteria for potential Hy's Law cases. Conclusion: It is likely the 40.5% seizure reduction with CBDV represents an appropriate pharmacological response in this population with focal seizures. The placebo response was, however, high, which may reflect the participants' expectations of CBDV, and a treatment difference from placebo was not observed. CBDV was generally well tolerated.
dc.language.isoeng
dc.publisherMary Ann Liebert
dc.relation.ispartofseriesCannabis and Cannabinoid Research;6(6)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectConvulsions - Tractament
dc.subjectCannabinoides - Ús terapèutic
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshSeizures
dc.subject.mesh/drug therapy
dc.subject.meshTreatment Outcome
dc.subject.meshCannabinoids
dc.titleA Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1089/can.2020.0075
dc.subject.decsconvulsiones
dc.subject.decs/farmacoterapia
dc.subject.decsresultado del tratamiento
dc.subject.decscannabinoides
dc.relation.publishversionhttps://doi.org/10.1089/can.2020.0075
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Brodie MJ] Epilepsy Unit, University of Glasgow, Glasgow, United Kingdom. [Czapinski P] Epilepsy and Migraine Treatment Center, Krakow, Poland. [Pazdera L] Vestra Clinics - Dedicated Research Clinics, Rychnov nad Kneznou, Czech Republic. [Sander JW] NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom. Chalfont Centre for Epilepsy, Chalfont St. Peter, United Kingdom. Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, Netherlands. [Toledo M] Unitat d’Epilèpsia, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Napoles M] GW Research Ltd, Cambridge, United Kingdom
dc.identifier.pmid33998885
dc.identifier.wos000621609100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record